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Abstract
Background: Paclitaxel is a potent anticancer drug that is effective against a wide spectrum of cancers. To overcome its bioavail-
ability problems arising from very poor aqueous solubility and tendency to recrystallize upon dilution, paclitaxel is commercially
formulated with co-solvents such as Cremophor EL® that are known to cause serious side effects during chemotherapy. Amphi-
philic cyclodextrins are favored oligosaccharides as drug delivery systems for anticancer drugs, having the ability to spontaneously
form nanoparticles without surfactant or co-solvents. In the past few years, polycationic, amphiphilic cyclodextrins were intro-
duced as effective agents for gene delivery in the form of nanoplexes. In this study, the potential of polycationic, amphiphilic cyclo-
dextrin nanoparticles were evaluated in comparison to non-ionic amphiphilic cyclodextrins and core–shell type cyclodextrin nano-
particles for paclitaxel delivery to breast tumors. Pre-formulation studies were used as a basis for selecting the suitable organic sol-
vent and surfactant concentration for the novel polycationic cyclodextrin nanoparticles. The nanoparticles were then extensively
characterized with particle size distribution, polydispersity index, zeta potential, drug loading capacity, in vitro release profiles and
cytotoxicity studies.
Results: Paclitaxel-loaded cyclodextrin nanoparticles were obtained in the diameter range of 80−125 nm (depending on the nature
of the cyclodextrin derivative) where the smallest diameter nanoparticles were obtained with polycationic (PC) βCDC6. A strong
positive charge also helped to increase the loading capacity of the nanoparticles with paclitaxel up to 60%. Interestingly, cyclo-
dextrin nanoparticles were able to stabilize paclitaxel in aqueous solution for 30 days. All blank cyclodextrin nanoparticles were
demonstrated to be non-cytotoxic against L929 mouse fibroblast cell line. In addition, paclitaxel-loaded nanoparticles have a signif-
icant anticancer effect against MCF-7 human breast cancer cell line as compared with a paclitaxel solution in DMSO.
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Conclusion: According to the results of this study, both amphiphilic cyclodextrin derivatives provide suitable nanometer-sized
drug delivery systems for safe and efficient intravenous paclitaxel delivery for chemotherapy. In the light of these studies, it can be
said that amphiphilic cyclodextrin nanoparticles of different surface charge can be considered as a promising alternative for self-
assembled nanometer-sized drug carrier systems for safe and efficient chemotherapy.
Introduction
Paclitaxel (PCX) is an effective wide-spectrum anticancer agent
which is isolated from the bark of the tree Taxus brevifolia and
further obtained semi-synthetically [1]. Its unique antimitotic
mechanism depends on inducing the microtubule stabilization
and inhibiting the depolymerization of microtubules [2]. PCX
binds to N-terminal 31 amino acids of the β-tubulin proteins in
microtubules and stabilizes (instead of inhibiting) microtubule
assembly to prevent cell division. On the other hand, PCX
causes cells to remain in G2/M phase. Microtubules formed by
the action of PCX are also dysfunctional and cause cell death
[3]. In spite of its promising antitumor activity, the drug has
presented considerable difficulties related to its intravenous
administration to patients. The most important of these chal-
lenges is the very low solubility of PCX in water (0.3 µg/mL)
[4]. To overcome poor solubility of PCX in water, the current
commercial injectable formulation consists of a 1:1 mixture of
anhydrous ethanol and Cremophor EL®, which is known to be
the cause of severe side effects including nephrotoxicity, neuro-
toxicity and hypersensitivity reactions [5,6]. Other major prob-
lems encountered in the clinical administration of PCX are
rapid recrystallization of the drug as a result of dilution in
isotonic saline or dextrose solution, leading to severe necrosis
and pain at injection site as well as reported incompatibility
with intravenous (iv) infusion sets [7]. In order to overcome
these side effects of PCX in clinical applications, alternative ap-
proaches are developed and evaluated to increase safety and
efficacy of chemotherapy with PCX.
A promising step was taken with the FDA approval of albumin
nanoparticle bound PCX (Abraxane®) in 2005 for breast cancer
treatment with a significantly lower dose [8]. This was consid-
ered a breakthrough in PCX formulation development as it
avoided the use of solubilizers, delivering the drug bound to the
nanocarriers in a considerably lower dose to target tissue.
Cyclodextrins (CDs) are cyclic oligosaccharides obtained
through enzymatic degradation of starch. The most frequently
used CDs in the pharmaceutical field are α-CD, β-CD and γ-CD
having 6, 7 and 8 subunits, respectively [9]. These molecules
have drawn attention as drug carrier systems for several years
because of their unique molecular structures and supramolecu-
lar capabilities. CDs, although hydrophilic in the external sur-
face, have hydrophobic cavity and this compartment allows
them to form strong inclusion complexes with non-polar drugs
or active molecules [10]. CDs are easily able to modulate physi-
cochemical properties of guest molecules, including solubility
and/or stability in biological medium. Despite all the advan-
tages, CDs have some challenges. For instance, it is well known
that β-CD has low solubility in water and causes haemolysis on
blood cells when administered parenterally [11,12]. To over-
come these challenges, natural CDs are modified with different
chemical groups to alter their structure and improve their bio-
compatibility [13-16].
Amphiphilic CDs have been synthesized to overcome problems
of natural CDs which enhance the interaction with drug mole-
cules and biological membranes [17,18]. Most importantly,
amphiphilic CDs possess the ability to spontaneously form
nanoparticles at the interface, depending on the preparation
method and physical and chemical properties of CD [19-22]. In
the literature, amphiphilic CDs were reported to spontaneously
self-assemble in the form of nanospheres or nanocapsules and
overcome haemolytic activity on blood cells for eventual
injectable nanoparticulate drug delivery [23-25].
The aim of this study was to evaluate and compare the potential
of polycationic amphiphilic CD nanoparticles as delivery
systems for effective and safe delivery of PCX in comparison to
its non-ionic or core–shell analogues. For this reason, two dif-
ferent cyclodextrin derivatives were used in this context,
namely the non-ionic 6OCaproβCD (MW: 1813 g/mol)
(Figure 1a) and the polycationic PC βCDC6 (3178 g/mol)
(Figure 1b). 6OCaproβCD is non-ionic as no charged groups are
present in the structure in the normal pH window (2–13) and it
was used to prepare negatively charged nanoparticles.
6OCaproβCD possesses 7 lipophilic groups on the primary face
whilst the polycationic PC βCDC6 has 7 cationic groups on the
primary face and 14 lipophilic groups on the secondary face.
Both nanoparticles were prepared by a nanoprecipitation tech-
nique which is based on spherical crystallites of the polymer
while precipitation occurs at the interface. In addition, chitosan
(Figure 1c) was used to coat the surface of the 6OCaproβCD
nanoparticles. Chitosan-coated 6OCaproβCD nanoparticles
(CS-6OCaproβCD) were also prepared and characterized. It was
aimed to increase the efficacy of PCX (Figure 1d) as a model
drug. All blank amphiphilic CD nanoparticles were optimized
for selection of organic solvent, ratio of organic phase to
aqueous phase and surfactant concentration to obtain monodis-
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Figure 1: Schematic representation of amphiphilic 6OCaproβCD (a), amphiphilic PC βCDC6 (b), chitosan (c) and paclitaxel (d).
perse particles with a diameter range around 80 to 125 nm.
Intended as chemotherapeutic nanocarriers, various PCX-loaded
amphiphilic CD nanoparticles were also evaluated for their drug
encapsulation, release profile and anticancer activity on MCF-7
human breast cancer cell line in particular. Safety and apoptotic
efficacy of blank and PCX-loaded cationic or anionic amphi-
philic CD nanoparticles were evaluated with cell culture studies
against a series of healthy and cancer cells.
The amphiphilic, cationic PC βCDC6 derivative was used as the
anticancer drug carrier delivery system for PCX for the first
time in this study. There are various studies in which this deriv-
ative is used as a gene transfer delivery system; however, there
is only example where this derivative was used as a drug
delivery system. This was a study regarding the non-polar anxi-
olytic drug diapezam realized by Mendez-Ardoy et al. [22]. Our
goal is to evaluate the potential of the polycationic CD nanopar-
ticles as an anticancer drug delivery system. In fact, these poly-
cationic CDs were evaluated for their intrinsic apoptotic effect
in our first paper [26] in unloaded blank nanoparticle form. This
study focuses on the nanocarrier properties and drug delivery
system potential of the polycationic CD nanoparticles for PCX,
which is an anticancer drug with several serious bioavaibility
and toxicity problems. PCX was selected as the target drug in
this study also for the fact that it is available on the market in
nanomedicine form, known as Abraxane®.
Results and Discussion
Pre-formulation studies
Nanoparticles are promising carriers for drugs due to their
tunable dimensions and shape. There are several factors that in-
fluence the particle size, particle distribution, surface charge,
homogeneity and shape of nanometer-sized drug delivery
systems. These factors have a subsequent influence on the bio-
distribution and the fate of the nanomedicine in the body [27].
In this case, the formulation parameters play an important role
on the mean diameter of the nanoparticles. Our primary concern
was to obtain an optimal particle size distribution with a diame-
ter less than 200 nm and a polydispersity index lower than 0.2;
therefore, the corresponding parameters were thoroughly
assessed.
The effect of different organic solvents used in the organic
phase on the mean particle size and polydispersity index (PDI)
of blank amphiphilic CD nanoparticles is given in Table 1. It is
clearly seen that among the various water-miscible solvents (re-
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Table 1: Effect of organic solvent on mean particle size, PDI and zeta potential values of formulations (CD amount is 0.5 mg/mL in all formulations)
(n = 3, ± standard deviation (SD)).
Nanoparticle formulations Solvent Particle diameter ± SD (nm) PDI ± SD Zeta potential (mV) ± SD
6OCaproβCD acetone 164 ± 5 0.62 ± 0.05 −26 ± 2.9
ethanol 104 ± 1 0.13 ± 0.02 −24 ± 0.3
methanol 367 ± 2 0.15 ± 0.03 −26 ± 1.4
CS-6OCaproβCD acetone 285 ± 5 0.34 ± 0.06 +57.2 ± 2.3
ethanol 122 ± 4 0.23 ± 0.03 +69.1 ± 1.6
methanol 399 ± 2 0.35 ± 0.03 +61 ± 3.1
PC βCDC6 acetone 124 ± 4 0.32 ± 0.05 +76 ± 0.2
ethanol 75 ± 2 0.16 ± 0.02 +61 ± 1.4
methanol 121 ± 6 0.51 ± 0.02 +65 ± 1.3
quired for the nanoprecipitation technique), ethanol is the
optimal solvent in this study in terms of mean diameter and PDI
for all CD nanoparticle formulations. The nanoprecipitation
method is mainly based on interfacial turbulence between a
miscible organic phase and an aqueous phase [28]. In nanopre-
cipitation, the polymer and drug is dissolved in a water-miscible
organic solvent, which diffuses from the organic phase into the
aqueous phase. Meanwhile, polymers in the organic phase tend
to spontaneously aggregate, forming spherical crystals, and thus
nanoparticles form rapidly [27,29].
As seen in Table 1, the mean particle size of the nanoparticles
varies greatly in the range between 75 to 400 nm for different
solvents, and ethanol gives the smallest diameter for all CD
nanoparticles. The effect of organic solvent selection on nano-
particle diameter was found to follow the order of methanol >
acetone > ethanol for 6OCaproβCD nanoparticles and
CS-6OCaproβCD nanoparticles, and acetone > methanol >
ethanol for PC βCDC6 nanoparticles. It is worth noting that
ethanol also gave the most monodisperse particles with an
acceptable polydispersity index (<0.2) (Table 1).
As expected, the core–shell nanoparticles CS-6OCaproβCD had
the largest size due to the chitosan coating on its surface,
and the PC βCDC6 nanoparticles were the smallest, probably
resulting from the likely electrostatic destabilization of larger
particles.
As is known, nanoparticle homogeneity is based on the proper-
ties of the organic solvent in the nanoprecipitation technique. It
is shown that ethanol is the optimum organic solvent for amphi-
philic CDs in this study. In the nanoprecipitation technique,
nanoparticle formation occurs as a result of interfacial turbu-
lence between two unequilibrated liquid phases. For the forma-
tion of turbulence, the liquid phases (organic phase and liquid
phase) used in this method must be miscible with each other.
Galindo-Rodriguez et al. investigated the influence of the dif-
ferent solvent types on NP formation in the nanoprecipitation
technique [30]. The solvent and solubility parameters were
calculated by using the dispersion force component, the polar
component, and the hydrogen bonding component. It was re-
ported that the smaller the difference between the solubility of
solute and solvent, the higher the affinity and the smaller the
particle size. They emphasized that the difference in polarity be-
tween ethanol/water is the smallest compared to the difference
between the other solvents/water, and the smallest particle size
is obtained in the formulation using ethanol [30]. In another
study, Khan et al. prepared gelatine nanoparticles by the nano-
precipitation technique with different organic solvents (metha-
nol, ethanol, acetone, n-propanol and acetonitrile) concluding
that only methanol and ethanol led to nanometer-sized particles
among those solvents that were studied. Furthermore, ethanol
was reported to provide the smallest particle size (250 nm) be-
tween these two organic solvents [31] in parallel to the findings
presented in Table 1.
As another major parameter influencing particle formation and
size, the effect of surfactant presence and concentration was de-
termined by investigating the mean particle size of amphiphilic
CD nanoparticles for 0, 0.1 and 0.5% w/v pluronic F68 (PF68)
dissolved in aqueous phase. Table 2 shows that the mean parti-
cle size increases in proportion with concentration of PF68.
The smallest particle size was obtained without the surfactant
for all nanoparticle formulations. This is found to be in accor-
dance with previous studies reported in the literature proving
that amphiphilic CDs are able to form nanoparticles without the
presence of surfactants [21,22,24,32-34] due to their favorable
self-alignment properties at air–water or oil–water interface
[35]. The mean particle size of amphiphilic CD nanoparticles
increased linearly with concentration of surfactant. Bilensoy et
al. evaluated the effect of the presence of PF68 in CD nanopar-
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Table 2: Effect of surfactant concentration on nanoparticle diameter and dispersity in ethanol (CD amount is 0.5 mg/mL in all formulations)
(n = 3, ± SD).
Nanoparticle formulations PF68 concentration (% w/v) Particle diameter ± SD (nm) PDI ± SD
6OCaproβCD 0 104 ± 1 0.13 ± 0.02
0.1 190 ± 4 0.17 ± 0.03
0.5 208 ± 5 0.23 ± 0.02
CS-6OCaproβCD 0 122 ± 4 0.23 ± 0.03
0.1 168 ± 6 0.15 ± 0.03
0.5 185 ± 4 0.33 ± 0.06
PC βCDC6 0 75 ± 2 0.16 ± 0.02
0.1 110 ± 7 0.37 ± 0.01
0.5 175 ± 5 0.47 ± 0.04
Table 3: Associated drug (%) and entrapment drug quantity (µg/mg) of amphiphilic CD nanoparticles for PCX (CD amount is 0.5 mg/mL and initial
PCX amount is 0.05 mg/mL in all formulations) (n = 3, ± SD).
Nanoparticle formulations Percentage associated drug ± SD Entrapment drug quantity ± SD (µg/mg)
6OCaproβCD 41 ± 2 4.4 ± 0.4
CS-6OCaproβCD 62 ± 5 5.6 ± 1.3
PC βCDC6 64 ± 2 6.3 ± 0.7
ticle formulations on cytotoxicity on L929, a healthy mouse fi-
broblast cell line. According to these results, it was suggested
that PF68 has no significant effect on size and drug loading
capacity of nanoparticles but dose-dependent toxicity could
occur on L929 fibroblast cells [36]. In another study, a polycat-
ionic, amphiphilic, cyclodextrin derivative was used to prepare
nanospheres and nanocapsules as drug delivery systems. When
the results are compared with this study in terms of particle size,
it can be concluded that the use of surfactant is linearly corre-
lated with the particle size [22].
Characterization of PCX-loaded amphiphilic
CD nanoparticles
According to pre-formulation studies described and discussed in
the previous section, it was decided that the most suitable sol-
vent is ethanol for all CD formulations. Each PCX-loaded nano-
particle formulation was prepared with ethanol and without any
surfactant (PF68).
Delivering the therapeutic load to the target site and main-
taining therapeutic blood levels for the drug in an effective dose
is the most important objective for targeted nanomedicines.
Drug encapsulation efficiency is highly affected by the nature
of the polymer/polysaccharide used to prepare the nanoparti-
cles. Therefore, in order to determine the effect of surface
charge on drug loading capacity of nanoparticles, PCX was
chosen as a model anticancer drug frequently used in chemo-
therapy for patients with breast cancer. The encapsulation effi-
ciency of amphiphilic CD nanoparticles is given in Table 3. The
quantity of loaded PCX was determined directly with a vali-
dated HPLC method and entrapment efficiency or associated
drug percentage were calculated with Equation 1 or Equation 2,
as described later in the Experimental section. As seen in
Table 3, the drug loading capacity of the nanoparticles was
strongly related to the surface charge of the CD nanoparticles.
As is known, PCX itself is negatively charged, so encapsula-
tion due to electrostatic interactions is favored for the cationic
CD nanoparticles, CS-6OCaproβCD and PC βCDC6, resulting
in a 1.5-fold higher loading for this drug in cationic nanoparti-
cles compared to the negatively charged 6OCaproβCD nanopar-
ticles as seen in Table 3.
According to these results, the CS coating increased drug
loading capacity of anionic 6OCaproβCD nanoparticles by
approximately 50%. In addition, the CS coating may provide
more efficient encapsulation area for PCX from aqueous media.
It can be said that this hypothesis is also valid for PC βCDC6
nanoparticles. This amphiphilic CD derivative has long aliphat-
ic chains terminated with amine groups. PC βCDC6 nanoparti-
cles are believed to encapsulate PCX not only in the hydro-
phobic cavity but also between the long cationic aliphatic
chains of the cyclodextrin as PCX and CD are co-nanoprecipi-
tated during the preparation method.
Table 4 shows the final mean particle size, PDI and zeta poten-
tial values of PCX-loaded amphiphilic CD nanoparticles. The
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mean diameter of PCX-loaded nanoparticles varies in the range
of 82 to 125 nm according to the type of CD used. They also
exhibit a narrow distribution as the preparation technique nano-
precipitation was kept standard for all formulations.
Table 4: Mean particle size, PDI and zeta potential of PCX-loaded
nanoparticles (CD amount is 0.5 mg/mL and initial PCX amount is





PDI ± SD Zeta potential
± SD (mV)
6OCaproβCD 113 ± 4 0.13 ± 1 −29 ± 2
CS-6OCaproβCD 125 ± 2 0.22 ± 4 +44 ± 3
PC βCDC6 82 ± 2 0.16 ± 5 +62 ± 1
In addition, drug loading did not cause significant changes in
mean diameter of the nanoparticles except that an increase in di-
ameter was observed for all nanoparticles. This suggests that the
drug is partially adsorbed as a layer on the nanoparticle surface
and partially encapsulated in the matrix due to charge interac-
tions since PCX is a molecular entity with a carboxilic acid end,
thereby anionic at neutral pH. Although the differences be-
tween the particle sizes of the blank and drug-loaded nanoparti-
cles are not statistically significant, the smallest difference is
seen in the CS-coated nanoparticles. The difference between the
particle sizes of the blank and drug-loaded nanoparticles may be
related to the localization of the drug. When the nanoparticles
were prepared, the drug and cyclodextrins were dissolved
together in the organic phase. Meanwhile, some of the drug is
encapsulated by the hydrophobic cavity of the cyclodextrins and
some of the drug is adsorbed on the surface of nanoparticles.
This drug on the surface of the nanoparticles changes the parti-
cle size. For CS-coated nanoparticles, the drug and cyclo-
dextrin were dissolved in the organic phase and then added to
the CS-containing water. The presence of chitosan in the
aqueous phase may cause a charge interaction between the
adsorbed drug on the surface of the nanoparticles and the
chitosan, resulting in a more rigid structure. In another previous
study, it was reported that the new amphiphilic CD derivative
PC βCDC6 is suitable to form stable nanoparticles with small
particle size [26]. The particle size of nanoparticulate drug
delivery systems play a direct and important role on cellular
uptake, systemic circulation, toxicity and stability of nanoparti-
cles [37,38]. It was reported that nanoparticles smaller than
200 nm can escape recognition by the mononuclear phagocytic
system (MPS) [39]. The prolonged circulation time for nanopar-
ticles, t, is needed to escape from MPS uptake in order to reach
the tumor tissue. The MPS is one of the most important factors
in preventing the prolonged circulation, affecting the biodistri-
bution of nanoparticles. In this way, more effective and safe
therapy can be provided with lower drug dose.
Figure 2: Time-dependent variation of particle size (nm) of PCX-
loaded amphiphilic CD nanoparticles stored in aqueous dispersion
form, (n = 3, ± SD).
Zeta potential measurements indicate that 6OCaproβCD has a
negative surface charge unlike the other formulations. In this
study, PC βCDC6 has a strong positive surface charge owing to
polycationic amino groups. This amphiphilic CD derivative was
previously used for gene delivery studies due to net positive
surface charge, facilitating the condensation of negatively
charged DNA to form polyplexes [40,41]. In addition,
CS-6OCaproβCD nanoparticles are also positively charged due
to coating with cationic polymer. It is known that chitosan is a
natural bioactive cationic polysaccharide derived from deacetyl-
ation of chitin and is well-characterized for its mucosal penetra-
tion enhancer property and apoptotic activity against cancer
cells [42]. To alter the surface charge of nanomaterials, chitosan
can be used as coating material in nanoparticles [43,44]. As a
result of the surface coating with chitosan, the zeta potential
value of 6OCaproβCD nanoparticles increased from −29 mV to
+44 mV as seen in Table 3. Unal et al., prepared uncoated and
CS-coated 6OCaproβCD nanocapsules for oral camptothecin
delivery. They reported that the CS coating increased the zeta
potential of nanocapsules from −11 to +10 mV [45,46].
Both CS-coated CD and PC βCDC6 were able to render a net
positive charge to the nanoparticles while 6OCaproβCD had a
charge around −25 mV. Nanoparticles with zeta potential be-
tween −10 and +10 mV are classified as neutral. Nanoparticles
with zeta potential greater than +30 mV and less than −30 mV
are considered as strongly charged [47]. According to this clas-
sification, two net positive nanoparticle formulations and a net
negative nanoparticle formulation were used as a nanometer-
sized drug delivery system for PCX in this study. These differ-
ences between the surface charge of CD nanoparticles allowed
the comparison of the effect of surface charge on drug loading
capacity, stability and anticancer activity in this study.
Furthermore, mean particle size distributions and PDI of the
blank and PCX-loaded nanoparticles were followed for one
month in aqueous form to determine the physical stability of
PCX-loaded amphiphilic CD nanoparticle dispersions. Figure 2,
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Figure 3 and Figure 4 show that there is no significant differ-
ence for particle size, PDI and zeta potential of PCX-loaded and
blank CD nanoparticle formulations (p > 0.05). PCX-loaded
nanoparticles maintained their stability for 30 days in ultrapure
water. This data shows that PCX crystals are not formed in
aqueous dilution, which is believed to improve the safety of the
drug delivery system.
Figure 3: Time-dependent variation of the PDI value of PCX-loaded
amphiphilic CD nanoparticles stored in aqueous dispersion form
(n = 3, ± SD).
Figure 4: Time-dependent variation of the zeta potential value of PCX-
loaded amphiphilic CD nanoparticles stored in aqueous dispersion
form (n = 3, ± SD).
PCX exists in a crystal form in aqueous media due to hydro-
phobic interaction between lipophilic groups [48,49]. Due to
this phenomenon, PCX is recrystallized in minutes as a result of
dilution in isotonic saline solution for intravenous (iv) infusion,
which is the preferred delivery route for chemotherapy. This is
one of the main problems of clinical application of PCX. In the
light of the physical stability studies depicted in Figures 2–4, it
can be said that all amphiphilic CD nanoparticles maintained
PCX in dispersed form within their hydrophobic matrix and
thus, ensured stability of drug in aqueous media, which is also
supported by previous studies for 6OCaproβCD nanocapsules
and nanospheres [24].
The in vitro release profile of PCX from CD nanoparticles was
determined using the dialysis bag method with HPLC as
detailed in the Experimental section. As seen in Figure 5, PCX
release from PC βCDC6 exhibited a markedly slower release
profile of up to 42 h compared with other formulations. The
release profiles indicated that in the first 5 h approximately 50%
of PCX was released from the CS-6OCaproβCD and 70% from
anionic 6OCaproβCD nanoparticles formulations, which can be
attributed to desorption of surface PCX. Meanwhile, a 50%
release time for PCX was found to be 8 h from PC βCDC6
nanoparticles. In addition, the release profile of PCX was found
to reach plateau levels at 8, 12 and 42 h for 6OCaproβCD,
CS-6OCaproβCD and PC βCDC6 nanoparticles, respectively.
Figure 5: Cumulative release profile of PCX from different amphiphilic
CD nanoparticles at pH 7.4 phosphate buffer solution under sink condi-
tions (n = 3, ± SD).
PCX carries a negative charge and therefore has a stronger
interaction with the positively charged CD, thus PCX release
from PC βCDC6 is slower than other formulations. The CS
coating of 6OCaproβCD nanoparticles also relatively slows
down the release. However, the core–shell approach is believed
to be insufficient to prolong the release of PCX as a result of
both the hydrophobic nanoparticle matrix and the strong posi-
tive charge due to the negative charge of PCX.
It was reported in the literature that large nanoparticles result in
a slower release profile than smaller nanoparticles [50]. Howev-
er, in this study, PC βCDC6 nanoparticles have the smallest par-
ticle size and the longer release profile, as seen in Figure 5. It
can therefore be suggested that the surface charge of nanoparti-
cle is directly effective on the drug release profile.
Cell culture studies
In order to determine the safety of blank amphiphilic CD nano-
particles and the anticancer efficacy of PCX-loaded amphi-
philic CD nanoparticles, L929 mouse fibroblast cells and MCF-
7 human breast cancer cell lines were used, respectively. Both
cell lines were grown and incubated in appropriate conditions
(see Experimental section for full experimental details).
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The cytotoxicity of blank amphiphilic CD nanoparticles was de-
termined on L929 mouse fibroblast cells with MTT assay. This
cell line is recommended by the U.S. Pharmacopeial Conven-
tion (USP) for the cytotoxicity evaluation of polymeric systems
and was therefore used. According to MTT assay, cell viability
for L929 cells is given in Figure 6.
Figure 6: Cytotoxicity of unloaded amphiphilic CD nanoparticles on
L929 mouse fibroblast cell line with MTT assay (CD concentration is
0.5 mg/mL in all formulation) (n = 3, ± SD).
It is clearly shown that all blank amphiphilic CD nanoparticle
formulations are non-cytotoxic on L929 fibroblast cells com-
pared with the control group (p > 0.05). It can therefore be con-
cluded that blank amphiphilic CD nanoparticles have no cyto-
toxic effect on healthy cells. It was previously reported that tox-
icity of blank amphiphilic CD nanocapsules and nanospheres
are concentration dependent and that they are also non-hemo-
lytic [24,45]. Therefore, these nanoparticles may be safe on
healthy cells as drug carrying systems.
To optimize the concentration of CD nanoparticles for cell cul-
ture studies, the inhibitory concentration 50 (IC50) value of
PCX was calculated on MCF-7 human breast cancer cell line.
For this purpose, MCF-7 cells were incubated with different
concentrations of PCX in dimethyl sulfoxide (DMSO). Non-
treated cells were incubated with DMEM alone and were used
as control group. Cell proliferation was determined and the IC50
value of PCX was calculated and the results are given in
Figure 7.
As seen in Figure 7, the IC50 of PCX is 250 nM for the MCF-7
cell line. This result agrees with the literature [51]. According to
the IC50 study results, nanoparticles loaded with 250 nM PCX
were further used for cell culture studies.
The anticancer activity of PCX-loaded nanoparticles was deter-
mined on MCF-7 cell lines. After an incubation period, cell
viability was calculated, as shown in Figure 8.
Figure 7: IC50 value of PCX solution in DMSO on MCF-7 human
breast cancer cell line (n = 3, ± SD).
Figure 8: Anticancer activity of PCX-loaded amphiphilic CD nanoparti-
cle formulations and PCX solution in DMSO on MCF-7 human breast
cancer cell line after 48 h of incubation (All CD nanoparticle formula-
tions and PCX solution contain 250 nM PCX) (n = 3, ± SD). Note that:
* p < 0.05 as compared with the control, and ╪ p < 0.05 as compared
with other CD nanoparticle formulations.
According to the results of anticancer activity studies on MCF-
7, PCX-loaded amphiphilic CD nanoparticles have higher cyto-
toxicity than PCX solution in DMSO (p < 0.05). The amphi-
philic CD nanoparticles and the drug solution carry an equiva-
lent amount of PCX (250 nM) during the cell culture study. The
cell viability in loaded CD nanoparticles is significantly differ-
ent from the PCX solution (p < 0.05). Moreover, the effect of
surface charge on viability of cancer cells can be clearly seen in
Figure 8. Anticancer activity increases with increasing surface
charge of nanoparticles. It was known that the cell membrane is
negatively charged so that cationic nanoparticles enhance inter-
action with the biological membrane. Positively charged nano-
particles can bind with negatively charged molecules (e.g.,
sialic acid, cholesterol, phospholipid) on cell membrane easier
than anionic nanoparticles [26,52]. In addition, the surface
charge of nanoparticles play an important role on cellular
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uptake and subcellular localization [53,54]. Another reason for
the cell viability differences of CD nanoparticles may be related
with drug release profiles. PCX shows anticancer activity by
stabilizing microtubules and blocking the cell in G2 or M phase
in cell cycle [55,56]. The duration of drug release of PCX-
loaded amphiphilic CD nanoparticles increases in the order of
6OCaproβCD < CS-6OCaproβCD < PC βCDC6. Therefore, the
amphiphilic CD nanoparticles carried different drug amounts
when they were taken up by MCF-7 cells. This can explain the
difference in the cell viability between CD nanoparticle formu-
lations.
Conclusion
In this study, 6OCaproβCD, CS-6OCaproβCD and PC βCDC6
nanoparticles were prepared and used as nanometer-sized
delivery systems and compared in terms of mean particle size,
zeta potential, drug loading capacity and drug release profile for
PCX, which is an effective anticancer agent over the wide spec-
trum various types of cancer. The findings strongly suggest that
positive charge can improve drug loading capacity, slow down
drug release and improve cellular interaction due to the nega-
tive charge of the cell membrane. Furthermore, unloaded or
loaded nanoparticle cytotoxic effects were demonstrated with
MTT assay in this study. In the light of the results of this study,
it is clearly demonstrated that anionic and cationic CD nanopar-
ticles are suitable carriers for PCX. Moreover, PC βCDC6 was
used to prepare nanoparticulate, anticancer drug delivery
systems for the first time in literature. Cationic CD nanoparti-
cles can be considered as promising carriers for PCX as well as
other lipophilic anticancer drugs for cancer therapy. In addition,
by formulating with anionic and cationic amphiphilic CDs, it
will be possible to enhance anticancer activity of drugs, over-
coming the problem of surfactant-induced toxicity. Finally, it
can be said that polycationic amphiphilic CDs are favorable,




Anionic 6OCapro βCD and PC βCDC6 were synthetized as de-
scribed previously in University of Sevilla, Spain [26]. PCX
(≥97% powder, MW: 853.91 g/mol) was purchased from Sigma-
Aldrich, Germany. The chitosan used for coating the nanoparti-
cles (Protasan UP G-113; MW: <200 kDa, viscosity:
<20 mPa·s), was purchased from Novamatrix, Norway. Cellu-
lose membrane dialysis tubing (avgerage flat width 25 mm,
MWCO: 14,000 Da) was purchased from Sigma-Aldrich,
Germany. All other chemicals used were of analytical grade and
obtained from Sigma-Aldrich. Ultrapure water was obtained
from a Millipore Simplicity 185 Ultrapure water system (Milli-
pore, France).
Methods
Preparation of unloaded or PCX-loaded amphiphilic
CD nanoparticles
PC βCDC6 nanoparticles and anionic 6OCaproβCD nanoparti-
cles were prepared according to the nanoprecipitation method as
described previously [26,28]. Briefly, 1 mg of PC βCDC6 or
6OCaproβCD was dissolved in 1 mL of organic solvent
(ethanol, methanol or acetone) (0.1% w/v). This organic phase
was added dropwise into aqueous phase (2 mL) containing
PF68 (0–0.5% w/v) under magnetic stirring at room tempera-
ture. Then, the organic phase was evaporated under vacuum at
40 °C to the desired final volume of 2 mL. To prepare
CS-coated 6OCaproβCD nanoparticles, the same technique was
employed in the presence of protosan (0.025%, w/v) in the
aqueous phase. According to the results of the pre-formulation
studies, optimal formulation parameters were selected for PCX-
loaded amphiphilic CD nanoparticles. To prepare drug-loaded
nanoparticles, PCX (0.1 mg) and cyclodextrin (1 mg) were
co-nanoprecipitated in 1 mL organic solvent and then organic
phase was poured in 2 mL ultrapure water using the conditions
previously given.
Mean particle size distribution and surface charge
The mean particle diameter (nm), PDI and zeta potential (mV)
of amphiphilic CD nanoparticles were determined by dynamic
light scattering (DLS) (NanoZS, Malvern Instruments, UK). All
formulations were measured at an angle of 173° for particle size
measurements and 12° for zeta potential measurements. All
formulations were measured at room temperature in triplicate
for thesize and zeta potential analysis.
Drug loading capacity and in vitro release profile of
PCX-loaded amphiphilic CD nanoparticles
The content of PCX in amphiphilic CD nanoparticle formula-
tions was quantified directly with a validated HPLC method
[32] (HP Agilent 1100 HPLC system, Germany). Briefly, PCX-
loaded nanoparticle formulations were lyophilized for 24 h
following centrifugation at 10,000 rpm for 15 min to remove
free PCX. The supernatant was collected and freeze-dried. The
lyophilized nanoparticle powder was dissolved in dichloro-
methane (DCM) to quantify nanoparticle-bound PCX (µg/mL).
The HPLC system consisted of reverse phase C18 column
(Hichrom 5, 250 × 4.6 mm, U.K.) and acetonitrile: ultrapure
water (70:30 v/v) as a mobile phase was delivered at a flow rate
of 1.00 mL/min. A 50 µL aliquot of sample was injected for
analysis. PCX was quantified by UV detection (λ = 227.4 nm)
at 25 °C. Drug loading was expressed as described in
Equation 1 and Equation 2 to clearly express the drug percent-
age bound to nanoparticles as well as drug entrapped per unit
polymer.




The in vitro cumulative release profile of PCX from CD nano-
particles was determined with the dialysis membrane technique
under sink conditions in a shaking water bath at 37 °C in PBS
pH 7.4. Briefly, drug-loaded nanoparticle dispersions were
added in the dialysis membrane (Sigma, cellulose membrane,
MWCO: 100,000 Da, Sigma Chemicals). The nanoparticle-con-
taining dialysis bags, closed with stoppers on both ends, were
placed in PBS pH 7.4 containing 0.1% Tween 80 at 37 °C to
provide sink conditions. The samples were taken from the medi-
um at specific time intervals and replaced with fresh PBS at the
same volume and temperature. The PCX amount in the samples
was determined with HPLC as described previously.
Physical stability of blank or drug-loaded
nanoparticles
In order to determine the physical stability of PCX in the nano-
particles, drug-loaded nanoparticles were stored in ultrapure
water at 4 °C and the mean particle size, PDI values and zeta
potential were obtained periodically for 30 days in aqueous
dispersion form to elucidate whether PCX crystals are formed
or any aggregation/precipitation is observed upon storage of the
nanoparticle dispersions.
Cell culture studies
In order to determine safety or anticancer efficacy of blank
amphiphilic CD nanoparticles, L929 mouse fibroblast cells or
MCF-7 human breast carcinoma cell lines were used, respec-
tively. Both cell lines were cultured in the same conditions as a
monolayer in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% fetal bovine serum (FBS), penicillin
(100 units/mL) and streptomycin (100 µg/mL). The cultures
were maintained at 37 °C in a humidified 5% CO2 incubator.
The cell lines were seeded in 96-well tissue culture plates at a
density of 1 × 103 cells/well in DMEM (100 µL), separately.
After the L929 cells reached confluence, DMEM was removed
from the cells and fresh medium containing blank amphiphilic
CD nanoparticles was replaced and incubated for 48 h. In order
to determine cell viability, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay was applied. For this
purpose, 20 µL of MTT solution in PBS (5 mg/mL) was added
in each well and incubated for 4 h. After incubation, 100 mL of
DMSO was added per well to dissolve formazan crystals. The
optical density (OD) was determined by a microplate reader
(Molecular Devices, USA) at 450 nm.
In order to determine the anticancer activity of loaded nanopar-
ticles, the IC50 value of PCX was calculated firstly. For this
purpose, after the MCF-7 cells reached full confluence, DMEM
was replaced with different concentrations of a PCX solution in
DMSO (50, 100, 250, 500, 1000 and 2000 nM) and incubated
for 48 h. After the incubation time, the MTT assay was applied
described above. According to the IC50 study, amphiphilic CD
nanoparticles were prepared and diluted with DMEM to contain
250 nM PCX. The control group consisted of cells incubated in
DMEM alone for two groups and PCX solution in DMSO for
the MCF-7 cell line. After that, using MTT assay, the cell
viability was determined.
Statistical Analysis
All statistical analyses were performed by Student’s t-test using
GraphPad Prism version 6 (San Diego, CA, USA). A value
of p < 0.05 was considered to denote a statistically significant
difference.
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